Avon shareholders to vote on parabens
This article was originally published in The Rose Sheet
Executive Summary
Shareholders to vote on resolution requiring direct-seller to conduct study on the feasibility of removing parabens from products at annual meeting May 1. Resolution is sponsored by investment firm Domini Social Investments and advocacy group Breast Cancer Action. In proxy statement filed with Securities and Exchange Commission March 27, Avon advises shareholders to oppose the resolution, noting "parabens are recognized as safe by The World Health Organization and the Cosmetic Ingredient Review Expert Panel. Advocacy group argues parabens are linked to breast cancer. Group is targeting Avon because of the direct-seller's association with efforts to raise money to fight the disease. Avon has at least 82 products containing parabens...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.